Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.54 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.54 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.52 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.52 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.52 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.50 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.49 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.49 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.48 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.48 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140447 | 0.90 | POLB (0.50) | P2RY12P2RY2P2RY1POLBP2RX3 | |
| SCHEMBL888156 | 0.87 | POLB (0.48) | P2RY12P2RY2P2RY1POLBP2RX3 | |
| SCHEMBL8174805 | 0.85 | POLB (0.59) | P2RY2P2RY1POLBP2RX3P2RX4 | |
| SCHEMBL8167619 | 0.85 | POLB (0.59) | P2RY2P2RY1POLBP2RX3P2RX4 | |
| SCHEMBL1883191 | 0.84 | POLB (0.53) | P2RY2P2RY1POLBP2RX3P2RX4 | |
| SCHEMBL8175190 | 0.84 | POLB (0.60) | P2RY2P2RY1POLBP2RX3P2RX2 | |
| SCHEMBL596737 | 0.84 | POLB (0.56) | P2RY2P2RY1POLBP2RX3P2RX4 | |
| SCHEMBL6904604 | 0.83 | AHCY (0.47) | P2RY12P2RY2P2RY1POLBENPP1 | |
| SCHEMBL2057095 | 0.82 | POLB (0.55) | P2RY2P2RY1POLBP2RX3P2RX4 | |
| SCHEMBL1140505 | 0.82 | POLB (0.60) | P2RY1POLBENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125856-B1 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN INC (US) | 2016-09-14 | — | — | EP | disclosed |
| US-20130095471-A1 | 3'-OH UNBLOCKED NUCLEOTIDES AND NUCLEOSIDES BASE MDIFIED WITH NON-CLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | WU WEIDONG (US) | 2013-04-18 | — | — | US | disclosed |
| US-8198029-B2 | 3'-OH unblocked nucleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA sequencing | LASERGEN, INC (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110200988-A1 | 3'-OH unblocked uncleotides and nucleosides base modified with non-cleavable, terminating groups and methods for their use in DNA squencing | AGILENT TECHNOLOGIES, INC. | 2011-08-18 | — | — | US | disclosed |
| US-7893227-B2 | Polymorphic identification; fluorescent dyes | LASERGEN, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| EP-2125856-A2 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | Lasergen, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008070749-A2 | PHOTOCLEAVABLE LABELED NUCLEOTIDES AND NUCLEOSIDES AND LABELED NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20080131952-A1 | Labeled nucleotides and nucleosides and methods for their use in DNA sequencing | AGILENT TECHNOLOGIES, INC. | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130095471-A1 | 3'-OH UNBLOCKED NUCLEOTIDES AND NUCLEOSIDES BASE MDIFIED WITH NON-CLEAVABLE, TERMINATING GROUPS AND METHODS FOR THEIR USE IN DNA SEQUENCING | NT5C3B, UNG, OGG1 | P2RY12 1275/4885P2RY2 1493/4885P2RY1 1278/4885 |
| US-20080131952-A1 | Labeled nucleotides and nucleosides and methods for their use in DNA sequencing | OGG1, NT5C3B, UNG | P2RY12 1263/4885P2RY2 934/4885P2RY1 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.